What is pharmacogenomic peptide design?

Pharmacogenomic peptide design is the computational process of using an individual's genetic variant data (SNPs) to identify protein targets and design peptide candidates that may interact with those targets. It combines pharmacogenomics (how genetics affect drug response) with computational peptide engineering.

How are SNPs used to design peptides?

SNPs (single nucleotide polymorphisms) are mapped to genes and their protein products. The protein's functional domains and binding sites are analyzed, and peptide candidates are computationally generated to interact with these regions. The candidates are then scored, ranked, and provided with synthesis protocols.

What types of genetic data can be used?

Any rsID identifier from genotyping services (23andMe, AncestryDNA, clinical WGS) can be submitted. The pipeline annotates each variant via ClinVar and maps clinically significant variants to their protein targets via UniProt.

Insights

Pharmacogenomic Peptide Design: From SNP to Therapeutic Candidate

Pharmacogenomics and peptide engineering are two of the fastest-growing fields in biomedicine. PepFold brings them together in a single automated pipeline.

The Convergence

Pharmacogenomics studies how genetic variation affects drug response. Since its formalization in the early 2000s, the field has demonstrated that single nucleotide polymorphisms (SNPs) can dramatically alter drug efficacy and safety, from warfarin dosing (VKORC1) to opioid sensitivity (OPRM1) to antipsychotic response (MTHFR C677T, Nadalin 2026).

Meanwhile, peptide therapeutics have evolved from niche biologics to a rapidly expanding drug class. Over 80 peptide drugs are FDA-approved, with hundreds more in clinical trials. Their advantages (high specificity, low toxicity, and tunable pharmacokinetics) make them natural candidates for personalized medicine.

The convergence of these fields, using an individual's pharmacogenomic profile to design personalized peptide candidates, represents a fundamentally new approach to drug discovery. Rather than screening compound libraries against generic targets, the starting point is the patient's own genetic data.

The Traditional Workflow (Weeks)

Before computational tools like PepFold, designing a peptide candidate from pharmacogenomic data required:

Manual literature review of each variant's clinical significance (hours to days)
Cross-referencing multiple databases (ClinVar, PharmGKB, UniProt) for gene-protein mapping
Identifying binding sites and functional domains through structural analysis
Designing peptide candidates using molecular modeling software (days)
Running structure predictions (AlphaFold or ESMFold, requires computational setup)
Scoring and ranking candidates manually
Planning synthesis protocols by consulting SPPS reference tables

Total time: 2 to 6 weeks of expert work for a single variant set, assuming access to all required databases and modeling tools.

The PepFold Workflow (Minutes)

PepFold automates the entire process end-to-end:

rsIDs → ClinVar annotation → UniProt mapping → AI peptide generation → ESMFold 3D prediction → Multi-dimensional scoring → Synthesis protocols → Report

Submit up to 50 rsIDs per analysis via API or web interface
Automated variant annotation with clinical significance filtering
Gene-to-protein mapping with binding site identification
AI-driven candidate generation with proprietary rational design fallback
3D structure prediction with per-residue confidence scores
Proprietary multi-dimensional scoring and ranking
Complete Fmoc-SPPS synthesis protocol for each top candidate
Downloadable HTML and PDF report

Total time: under 2 minutes. Total cost: from 50 EUR per analysis.

Who Uses This

Pharma R&D Teams

Screen genetic variants against peptide candidates to identify leads faster. Reduce the design phase from weeks to minutes for early-stage discovery.

Academic Researchers

Generate publish-ready data with full methodology transparency. Standardized reports with 3D viewers and scoring breakdowns.

Clinical Research Groups

Build pharmacogenomic profiles for patient cohorts. Understand variant-specific therapeutic opportunities at scale via the API.

Nutraceutical Companies

Design targeted peptide-based supplements informed by individual genetic profiles. From consumer genotyping data to formulation candidates.

Scientific Foundation

The pharmacogenomics field is well-established, with FDA approvals of personalized therapeutics involving biomarkers increasing rapidly (Sadee 2023, Pharmacological Reviews, cited 233 times). SNP-based drug response profiling is standard practice for drugs like warfarin, clopidogrel, and codeine.

Peptide drug design has likewise matured, with computational methods now standard in the discovery pipeline (Erckes 2026, Drug Discovery Today). AI-driven approaches, including protein language models like Evo 2 and structure predictors like ESMFold, are accelerating candidate generation by orders of magnitude.

PepFold integrates these established fields into a unified pipeline, adding proprietary scoring and design algorithms to bridge the gap between genomic data and actionable synthesis protocols.

From your variants to synthesis-ready peptides

Submit rsIDs from any genotyping service. Full pharmacogenomic report in under two minutes.

Get Started Read Methodology